# Feasibility of a Chemotherapy With Docetaxel-Prednisone for Castration-resistant Metastatic Prostate Cancer Elderly Patients

> **NCT01254513** · PHASE2 · COMPLETED · sponsor: **UNICANCER** · enrollment: 66 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Docetaxel every 3 weeks + Prednisone
- **DRUG:** Docetaxel weekly+ Prednisone

## Key facts

- **NCT ID:** NCT01254513
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12-09
- **Primary completion:** 2014-05-10
- **Final completion:** 2017-04-27
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2021-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01254513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01254513, "Feasibility of a Chemotherapy With Docetaxel-Prednisone for Castration-resistant Metastatic Prostate Cancer Elderly Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01254513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*